Protocols

Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study

→ Ultragenyx $RARE and its partners at Kyowa Hakko Kirin landed a priority review for burosumab to treat pediatric and adult patients with X-Linked Hypophosphatemia. The accelerated PR gives them a shot at an April 17, 2018 PDUFA date.

→ Genfit (Euronext: GNFT) is raising €150 million so it can wrap up its Phase III for elafibranor in NASH and take the data to regulators.

→ France’s Biophytis has raised €10.4 million for mid-stage studies of its drugs for age-related diseases. The biotech is working on sarcopenia and age-related macular degeneration.

 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->